Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges [NA]
Completed clinical trial evaluating economics and social psychology–inspired interventions to improve opioid prescribing safety via electron…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Virtual Reality for Chronic Pain and Opioid Use Disorder Pilot [NA]
A pilot clinical trial from Albert Einstein College of Medicine assessing virtual reality therapy for chronic pain and opioid use disorder c…
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment [Phase 2]
Phase 2 clinical trial evaluating mirtazapine for methamphetamine use in patients with opioid use disorder on medication-assisted treatment;…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Cognitive Functioning in Opioid Use Disorder [NA]
The clinical trial evaluating cognitive functioning in individuals with opioid use disorder has been terminated; the update does not report …
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: Opioid Use Disorder and Pain
A Yale University-led clinical trial is recruiting to study opioid use disorder with an age- and sex-matched healthy control group. The stud…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Application Based Addiction Treatment Adherence Trial [NA]
The Cleveland Clinic–sponsored trial evaluating application-based adherence strategies for opioid use disorder has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence [NA]
Completed SMART trial evaluating adherence to buprenorphine-naloxone for medication-assisted treatment of opioid use disorder. The entry not…
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder [NA]
A completed clinical trial evaluating a pharmacist-integrated collaborative model of medication treatment for opioid use disorder.
-
FDA approval · 2025-02-24FDA Approved: LOFEXIDINE HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
The FDA approved a generic lofexidine hydrochloride product from Novadoz Pharmaceuticals LLC under an Original Application to help alleviate…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a buprenorphine and naloxone product manufactured by Mylan Pharmaceuticals Inc., expanding acces…
-
FDA approval · 2025-02-21FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine extended-release injection) from Indivior Inc. The action relates t…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA supplemental approval for a generic buprenorphine/naloxone product from Dr. Reddy's Laboratories Inc.
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine hydrochloride (PAI Holdings) under an ANDA, reflecting an updated or additional fo…
-
FDA approval · 2025-02-21FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
FDA approved a supplemental application for Suboxone (buprenorphine hydrochloride, naloxone hydrochloride) from Indivior Inc. to modify the …
-
FDA approval · 2025-02-21FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV (buprenorphine/naloxone) from Orexo US, Inc.
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Lannett Company's buprenorphine and naloxone product, making a generic buprenorphine/naloxone op…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Buprenorphine HCl and Naloxone HCl from Amneal Pharmaceuticals LLC. The product is used for trea…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Buprenorphine and Naloxone from Actavis Pharma, Inc. This action supplements an existing regulat…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Buprenorphine and Naloxone from Sun Pharmaceutical Industries, updating the product's labeling.
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for Alvogen's buprenorphine/naloxone sublingual film, enabling the generic product to be marketed fo…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
The FDA approved a supplemental application for a generic buprenorphine/naloxone product from Rhodes Pharmaceuticals L.P. The approval confi…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for a generic buprenorphine and naloxone product intended for the treatment of opioid dependence, su…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for buprenorphine submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
FDA approved Accord Healthcare's supplemental ANDA for buprenorphine hydrochloride and naloxone hydrochloride dihydrate, a generic product i…
-
FDA approval · 2025-02-21FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for buprenorphine from Hikma Pharmaceuticals USA Inc. under the approved ANDA.